%0 Journal Article
%T Molecular Markers of Pancreatic Cancer: A 10-Year Retrospective Review of Molecular Advances.
%A Jacks BE
%A Ekpemiro CU
%A Adeosun AA
%A Ogbonna UO
%A Ogundiran FT
%A Babalola F
%A Onyechi NP
%A Ajayi OO
%A Boms MG
%A Nwanguma AN
%A Udo UA
%A Okobi OE
%A Ohikhuai EE
%A Evbayekha EO
%A Jacks BE
%A Ekpemiro CU
%A Adeosun AA
%A Ogbonna UO
%A Ogundiran FT
%A Babalola F
%A Onyechi NP
%A Ajayi OO
%A Boms MG
%A Nwanguma AN
%A Udo UA
%A Okobi OE
%A Ohikhuai EE
%A Evbayekha EO
%J Cureus
%V 14
%N 9
%D Sep 2022
%M 36299966
暂无%R 10.7759/cureus.29485
%X Pancreatic cancer remains the third leading cause of death amongst men and women in the United States. Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer maintains its reputation of being the most aggressive with a poor prognosis. One of the contributing factors to the high mortality of PDAC is the absence of biomarkers for early detection of disease and the complexity of tumor biology and genomics. In this review, we explored the current understanding of epigenetics and diagnostic biomarkers in PDAC and summarized recent advances in molecular biology. We discussed current guidelines on diagnosis, prognosis, and treatment, especially in high-risk individuals. We also reviewed studies that have touched on identifying biomarkers and the role they play in making early diagnosis although there are currently no screening tools for PDAC. We explored the recent understanding of epigenetic alterations of PDAC and the future implications for early detection and prognosis. In conclusion, the new and emerging advances in the detection and treatment of PDAC can lead to an improvement in the current outcome of PDAC.